Literature DB >> 29909548

Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.

Kristian W Pajtler1,2,3, Ji Wen4, Martin Sill1,2, Tong Lin5, Wilda Orisme4, Bo Tang4, Jens-Martin Hübner1,2, Vijay Ramaswamy6,7, Sujuan Jia4, James D Dalton4, Kelly Haupfear4, Hazel A Rogers8, Chandanamali Punchihewa4, Ryan Lee4, John Easton9, Gang Wu9, Timothy A Ritzmann8, Rebecca Chapman8, Lukas Chavez1,2, Fredrick A Boop10, Paul Klimo10, Noah D Sabin11, Robert Ogg11, Stephen C Mack7,12, Brian D Freibaum13, Hong Joo Kim13, Hendrik Witt1,2,3, David T W Jones1,2, Baohan Vo14, Amar Gajjar15, Stan Pounds5, Arzu Onar-Thomas5, Martine F Roussel14, Jinghui Zhang9, J Paul Taylor13,16, Thomas E Merchant17, Richard Grundy8, Ruth G Tatevossian4, Michael D Taylor7, Stefan M Pfister1,2,3, Andrey Korshunov18,19, Marcel Kool1,2, David W Ellison20.   

Abstract

Of nine ependymoma molecular groups detected by DNA methylation profiling, the posterior fossa type A (PFA) is most prevalent. We used DNA methylation profiling to look for further molecular heterogeneity among 675 PFA ependymomas. Two major subgroups, PFA-1 and PFA-2, and nine minor subtypes were discovered. Transcriptome profiling suggested a distinct histogenesis for PFA-1 and PFA-2, but their clinical parameters were similar. In contrast, PFA subtypes differed with respect to age at diagnosis, gender ratio, outcome, and frequencies of genetic alterations. One subtype, PFA-1c, was enriched for 1q gain and had a relatively poor outcome, while patients with PFA-2c ependymomas showed an overall survival at 5 years of > 90%. Unlike other ependymomas, PFA-2c tumors express high levels of OTX2, a potential biomarker for this ependymoma subtype with a good prognosis. We also discovered recurrent mutations among PFA ependymomas. H3 K27M mutations were present in 4.2%, occurring only in PFA-1 tumors, and missense mutations in an uncharacterized gene, CXorf67, were found in 9.4% of PFA ependymomas, but not in other groups. We detected high levels of wildtype or mutant CXorf67 expression in all PFA subtypes except PFA-1f, which is enriched for H3 K27M mutations. PFA ependymomas are characterized by lack of H3 K27 trimethylation (H3 K27-me3), and we tested the hypothesis that CXorf67 binds to PRC2 and can modulate levels of H3 K27-me3. Immunoprecipitation/mass spectrometry detected EZH2, SUZ12, and EED, core components of the PRC2 complex, bound to CXorf67 in the Daoy cell line, which shows high levels of CXorf67 and no expression of H3 K27-me3. Enforced reduction of CXorf67 in Daoy cells restored H3 K27-me3 levels, while enforced expression of CXorf67 in HEK293T and neural stem cells reduced H3 K27-me3 levels. Our data suggest that heterogeneity among PFA ependymomas could have clinicopathologic utility and that CXorf67 may have a functional role in these tumors.

Entities:  

Keywords:  CXorf67; DNA methylation profiling; Ependymoma; H3 K27-trimethylation; H3 K27M; Molecular heterogeneity; PRC2

Mesh:

Substances:

Year:  2018        PMID: 29909548      PMCID: PMC6105278          DOI: 10.1007/s00401-018-1877-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  53 in total

1.  Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma.

Authors:  Francesca Micci; Ioannis Panagopoulos; Bodil Bjerkehagen; Sverre Heim
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  DisMeta: a meta server for construct design and optimization.

Authors:  Yuanpeng Janet Huang; Thomas B Acton; Gaetano T Montelione
Journal:  Methods Mol Biol       Date:  2014

3.  Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.

Authors:  Pooja Panwalkar; Jonathan Clark; Vijay Ramaswamy; Debra Hawes; Fusheng Yang; Christopher Dunham; Stephen Yip; Juliette Hukin; Yilun Sun; Matthew J Schipper; Lukas Chavez; Ashley Margol; Melike Pekmezci; Chan Chung; Adam Banda; Jill M Bayliss; Sarah J Curry; Mariarita Santi; Fausto J Rodriguez; Matija Snuderl; Matthias A Karajannis; Amanda M Saratsis; Craig M Horbinski; Anne-Sophie Carret; Beverly Wilson; Donna Johnston; Lucie Lafay-Cousin; Shayna Zelcer; David Eisenstat; Marianna Silva; Katrin Scheinemann; Nada Jabado; P Daniel McNeely; Marcel Kool; Stefan M Pfister; Michael D Taylor; Cynthia Hawkins; Andrey Korshunov; Alexander R Judkins; Sriram Venneti
Journal:  Acta Neuropathol       Date:  2017-07-21       Impact factor: 17.088

4.  Intracranial ependymomas in childhood: recurrence, reoperation, and outcome.

Authors:  Matthieu Vinchon; Pierre Leblond; Rémy Noudel; Patrick Dhellemmes
Journal:  Childs Nerv Syst       Date:  2004-12-14       Impact factor: 1.475

5.  Evidence of H3 K27M mutations in posterior fossa ependymomas.

Authors:  Marco Gessi; David Capper; Felix Sahm; Kristin Huang; Andreas von Deimling; Stephan Tippelt; Gudrun Fleischhack; Daniel Scherbaum; Joachim Alfer; Björn-Ole Juhnke; Katja von Hoff; Stefan Rutkowski; Monika Warmuth-Metz; Lukas Chavez; Stefan M Pfister; Torsten Pietsch; David T W Jones; Dominik Sturm
Journal:  Acta Neuropathol       Date:  2016-08-18       Impact factor: 17.088

6.  Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).

Authors:  John-Paul Kilday; Biswaroop Mitra; Caroline Domerg; Jennifer Ward; Felipe Andreiuolo; Teresa Osteso-Ibanez; Audrey Mauguen; Pascale Varlet; Marie-Cecile Le Deley; James Lowe; David W Ellison; Richard J Gilbertson; Beth Coyle; Jacques Grill; Richard G Grundy
Journal:  Clin Cancer Res       Date:  2012-02-14       Impact factor: 12.531

7.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

8.  A prognostic gene expression signature in infratentorial ependymoma.

Authors:  Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Aditya Raghunathan; David Ellison; Richard Gilbertson; Brian Vaillant; Stewart Goldman; Roger J Packer; Maryam Fouladi; Ian Pollack; Tom Mikkelsen; Michael Prados; Antonio Omuro; Riccardo Soffietti; Alicia Ledoux; Charmaine Wilson; Lihong Long; Mark R Gilbert; Ken Aldape
Journal:  Acta Neuropathol       Date:  2012-02-10       Impact factor: 17.088

Review 9.  MR assessment of pediatric hydrocephalus: a road map.

Authors:  Charles Raybaud
Journal:  Childs Nerv Syst       Date:  2015-09-04       Impact factor: 1.475

10.  Genetic abnormalities detected in ependymomas by comparative genomic hybridisation.

Authors:  M Carter; J Nicholson; F Ross; J Crolla; R Allibone; V Balaji; R Perry; D Walker; R Gilbertson; D W Ellison
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

View more
  77 in total

Review 1.  Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.

Authors:  Flor M Mendez; Felipe J Núñez; Maria B Garcia-Fabiani; Santiago Haase; Stephen Carney; Jessica C Gauss; Oren J Becher; Pedro R Lowenstein; Maria G Castro
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

2.  Integrating ependymoma molecular subgroups into clinical trials.

Authors:  Sriram Venneti
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

3.  EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.

Authors:  Jens-Martin Hübner; Torsten Müller; Dimitris N Papageorgiou; Monika Mauermann; Jeroen Krijgsveld; Robert B Russell; David W Ellison; Stefan M Pfister; Kristian W Pajtler; Marcel Kool
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

4.  Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost.

Authors:  Michal Zapotocky; Kiran Beera; Jenny Adamski; Normand Laperierre; Sharon Guger; Laura Janzen; Alvaro Lassaletta; Liana Figueiredo Nobre; Ute Bartels; Uri Tabori; Cynthia Hawkins; Stacey Urbach; Derek S Tsang; Peter B Dirks; Michael D Taylor; Eric Bouffet; Donald J Mabbott; Vijay Ramaswamy
Journal:  Cancer       Date:  2019-02-15       Impact factor: 6.860

5.  Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.

Authors:  Santhosh A Upadhyaya; Giles W Robinson; Arzu Onar-Thomas; Brent A Orr; Catherine A Billups; Daniel C Bowers; Anne E Bendel; Tim Hassall; John R Crawford; Sonia Partap; Paul G Fisher; Ruth G Tatevossian; Tiffany Seah; Ibrahim A Qaddoumi; Anna Vinitsky; Gregory T Armstrong; Noah D Sabin; Christopher L Tinkle; Paul Klimo; Danny J Indelicato; Frederick A Boop; Thomas E Merchant; David W Ellison; Amar Gajjar
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

6.  Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.

Authors:  Bahattin Tanrıkulu; Ayça Erşen Danyeli; M Memet Özek
Journal:  Childs Nerv Syst       Date:  2020-02-05       Impact factor: 1.475

7.  Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.

Authors:  David Castel; Thomas Kergrohen; Arnault Tauziède-Espariat; Alan Mackay; Samia Ghermaoui; Emmanuèle Lechapt; Stefan M Pfister; Christof M Kramm; Nathalie Boddaert; Thomas Blauwblomme; Stéphanie Puget; Kévin Beccaria; Chris Jones; David T W Jones; Pascale Varlet; Jacques Grill; Marie-Anne Debily
Journal:  Acta Neuropathol       Date:  2020-03-19       Impact factor: 17.088

Review 8.  Developmental origins and emerging therapeutic opportunities for childhood cancer.

Authors:  Mariella Filbin; Michelle Monje
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

9.  Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.

Authors:  Martin Benesch; Martin Mynarek; Hendrik Witt; Monika Warmuth-Metz; Torsten Pietsch; Brigitte Bison; Stefan M Pfister; Kristian W Pajtler; Marcel Kool; Ulrich Schüller; Klaus Pietschmann; Björn-Ole Juhnke; Stephan Tippelt; Gudrun Fleischhack; Irene Schmid; Christof M Kramm; Peter Vorwerk; Andreas Beilken; Carl Friedrich Classen; Pablo Hernáiz Driever; Gabriele Kropshofer; Thomas Imschweiler; Andreas Lemmer; Rolf-Dieter Kortmann; Stefan Rutkowski; Katja von Hoff
Journal:  Oncologist       Date:  2019-03-08

10.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.